Trial Outcomes & Findings for Design Improvements With SONNET 3 (NCT NCT06597747)

NCT ID: NCT06597747

Last Updated: 2025-12-31

Results Overview

The proportion of participants reporting improvement in design aspects of SONNET 3 (EAS) on a user survey

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

20 participants

Primary outcome timeframe

Measured 1 month after baseline

Results posted on

2025-12-31

Participant Flow

Participant milestones

Participant milestones
Measure
SONNET 3 (EAS)
Participants complete a take-home trial using SONNET 3 (EAS) audio processor
Overall Study
STARTED
20
Overall Study
COMPLETED
20
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Design Improvements With SONNET 3

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
SONNET 3 (EAS)
n=20 Participants
Participants complete a take-home trial using SONNET 3 (EAS) audio processor
Age, Continuous
44.7 years
STANDARD_DEVIATION 24.1 • n=1000 Participants
Sex: Female, Male
Female
13 Participants
n=1000 Participants
Sex: Female, Male
Male
7 Participants
n=1000 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=1000 Participants
Race (NIH/OMB)
Asian
2 Participants
n=1000 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=1000 Participants
Race (NIH/OMB)
Black or African American
5 Participants
n=1000 Participants
Race (NIH/OMB)
White
12 Participants
n=1000 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=1000 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=1000 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=1000 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
20 Participants
n=1000 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=1000 Participants
Region of Enrollment
United States
20 Participants
n=1000 Participants
Cochlear Implant Experience
6.1 years
STANDARD_DEVIATION 5.3 • n=1000 Participants

PRIMARY outcome

Timeframe: Measured 1 month after baseline

The proportion of participants reporting improvement in design aspects of SONNET 3 (EAS) on a user survey

Outcome measures

Outcome measures
Measure
SONNET 3 (EAS)
n=20 Participants
Participants complete a take-home trial using SONNET 3 (EAS) audio processor
Participants Reporting Improvement With SONNET 3 Design
20 Participants

SECONDARY outcome

Timeframe: Measured after study completion, an average of 7.5 months

Score on a 6-point Likert scale (1 = Strongly Disagree to 6 = Strongly Agree; higher scores indicate better outcomes). Values reported are the average scores on subsections of the audiologist survey.

Outcome measures

Outcome measures
Measure
SONNET 3 (EAS)
n=3 Participants
Participants complete a take-home trial using SONNET 3 (EAS) audio processor
Audiologist Satisfaction Ratings
SONNET 3 Design
5.4 Score on 6-point Likert scale
Standard Deviation 0.3
Audiologist Satisfaction Ratings
MAESTRO 11
5.5 Score on 6-point Likert scale
Standard Deviation 0.5

Adverse Events

SONNET 3 (EAS)

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
SONNET 3 (EAS)
n=20 participants at risk
Participants complete a take-home trial using SONNET 3 (EAS) audio processor
Ear and labyrinth disorders
Adverse Device Effect
5.0%
1/20 • Number of events 1 • Measured through study completion, an average of 7.5 months

Additional Information

Clinical Research Manager

MED-EL Corporation

Phone: 888-633-3524

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place